BLTE · Belite Bio, Inc
$162.80
-3.48 (-2.09%)
At close · Aug 14
Market Cap
$6.53B
Shares
40.09M
Belite Bio, Inc Earnings Call Transcripts
Every quarterly earnings call for Belite Bio, Inc (BLTE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2026-07-08
Belite Bio, Inc Q2 FY2026 Earnings Call
Confident tone
NDA submission and FDA path for Stargardt disease
Financial position and operating expenses
Manufacturing and supply readiness
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-20
Earnings conference call (announced in 6-K)
Confident tone
NDA submission and FDA approval timeline
Financial position and operating expenses
Dragon 2 / Japan registration trial
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-12-31
Belite Bio, Inc Q4 FY2025 Earnings Call
Confident tone
DRAGON Phase 3 trial results
Prevalence and pediatric expansion
NDA submission and regulatory pathway
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q2
2025-06-30
Belite Bio, Inc Q2 FY2025 Earnings Call
Confident tone
Tinlarebant clinical progress
Geographic atrophy (PHOENIX) trial
Commercialization planning
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Belite Bio, Inc Q1 FY2025 Earnings Call
Confident tone
Phase 3 DRAGON (Stargardt) interim results
Tinlarebant drug profile and safety
PHOENIX Phase 3 trial in geographic atrophy
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Belite Bio, Inc Q4 FY2024 Earnings Call
Confident tone
Phase 3 DRAGON trial in Stargardt disease
Enrollment dropout rates
Phase 3 PHOENIX trial in GA
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-19
Belite Bio, Inc Q3 FY2024 Earnings Call
Confident tone
Tinlarebant clinical pipeline progress
Phase 2 Stargardt efficacy results
Geographic atrophy positioning vs complement inhibitors
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Belite Bio, Inc Q2 FY2024 Earnings Call
Confident tone
Tinlarebant clinical programs
Japan regulatory strategy
Phase II Stargardt data
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Belite Bio, Inc Q1 FY2024 Earnings Call
Confident tone
Stargardt disease Phase 2 data
Stargardt Phase 3 (DRAGON) progress
Geographic Atrophy (GA) Phase 3
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Belite Bio, Inc Q4 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Belite Bio, Inc Q3 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Belite Bio, Inc Q2 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Belite Bio, Inc Q1 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Belite Bio, Inc Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q2
2022-06-30
Belite Bio, Inc Q2 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–15 of 15 earnings calls
Key facts
CIK
1889109
CUSIP
07782B104
13F (30d)
82 filings
81 filers
Visit website
Investor relations